AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04160026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine
Description: Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
Study NCT04160026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monthly intermittent preventive treatment with sulfadoxine-pyrimethamine
Description: Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
Study NCT04160026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine with targeted information transfer
Description: Feasibility study to assess adherence to guidelines among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
Study NCT00932542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eutectic mixture
Description: The eutectic mixture of lidocaine + prilocaine + bupivacaine.
Study NCT00932542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00932542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 2,5%; prilocaine 2,5%
Description: lidocaine 2,5%; prilocaine 2,5%
Study NCT01962532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: JNJ-42756493
Description: JNJ-42756493 dose escalation starting at dose of 2 mg orally daily for 21-day cycles and 28 day cycles Intermitting dosing regimen (7 days on and 7 days off) up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.
Study NCT01962532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: JNJ-42756493
Description: Recommended Phase 2 JNJ-42756493 dose determined in Part 1 administered orally for 28-days cycles (Intermitting dosing regimen).
Study NCT01005082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low salt diet
Study NCT01005082 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water therapy alone
Study NCT02803008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation number - SR15-46-Z13-072)
Study NCT00522821 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: intravenous immunoglobulins
Description: * Adults: 600 mg/kg bodyweight every 3 weeks~* Children: 800 mg/kg bodyweight every 3 week
Study NCT00522821 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: antibiotics
Description: * Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.~* Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid.
Study NCT03114293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: The app includes an EBPI and physical activity feedback
Study NCT03843372 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula
Description: All of participants will be received one night high flow nasal cannula and another night for continuous positive airway pressure.
Study NCT03843372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: All of participants will be received one night high flow nasal cannula and another night for continuous positive airway pressure.
Study NCT00572260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin 6 mg/kg IV
Description: daptomycin 6 mg/kg IV given during induction phase as a one-time prophylactic dose for patients undergoing cardiac valve replacement and coronary artery bypass grafting (CABG) who are at increased risk for infection due to methicillin-resistant Staphylococcus aureus (MRSA)
Study NCT04010409 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04163848 — intervention group
Intervention type: OTHER
Intervention: Pollution
Description: CO2 equivalent productions related to anesthetic gases use during general anesthesia for laparoscopic surgery
Study NCT02310074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulsatile Gonadotropin Releasing Hormone
Study NCT02310074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: Human chorionic gonadotropin (hCG)
Study NCT02310074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urinary Follicle-Stimulating Hormone
Description: Urinary Follicle-Stimulating Hormone (uFSH)
Study NCT03769649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CelluTite
Description: CelluTite: Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
Study NCT03240419 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Bifidobacterium BB12 and Lactobacillus Rhamosus LGG (50%:50%) capsules.
Study NCT03240419 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule manufactured to mimic probiotic capsules.
Study NCT03163641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue Oasys
Description: Bandage Contact Lens
Study NCT03163641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ocular Bandage Gel
Description: 0.75% crosslinked HA
Study NCT03163641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ocular Bandage Gel
Description: 0.75% crosslinked HA
Study NCT04789031 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS)
Description: Patients received a renal specific ONS (Novasource Renal, Nestle) providing 475 kcal and 21.7g of protein per serving on a daily basis for 6 months. This was a ready-to- drink formula available in a tetrabrik pack. Patients consumed the product 30 minutes after commencing their dialysis session or at home after completion of dialysis.
Study NCT01661764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentanoic acid and docosahexanoic acid
Description: 1395 mg EPA plus 1125 mg DHA daily for 24 weeks
Study NCT01421498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: 12 weeks
Study NCT01661764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oleic Acid
Description: Placebo
Study NCT01421498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage Form: Ophthalmic Solution Frequency: BID Duration: 12 weeks
Study NCT04067869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood sample containing 3 ethylene-diamine-tetra-acetic acid tubes (7ml), 3 dry tubes (7ml) and 5 citrated tubes, ie 9 tubes
Study NCT00572091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTMA Implant
Description: Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein.
Study NCT03165773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal
Description: Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
Study NCT03165773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corn grits
Description: Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
Study NCT01765296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649
Description: 2 mg capsule
Study NCT01765296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 200 mg capsule
Study NCT01765296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mimic for CG100649 2 mg capsule and for celecoxib 200 mg capsule
Study NCT01619852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: .9 normal saline placebo
Description: Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.
Study NCT01619852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group L (lidocaine)
Description: Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
Study NCT02536820 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychoneuroimmune therapy
Study NCT02536820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Actual diabetes treatment in each participant
Study NCT03586908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHP-201 0.5% ophthalmic solution (topical eye drop)
Description: D1, D7: PHP-201 0.5% topical eye drop OU QD(AM), D2\~D6: PHP-201 0.5% topical eye drop OU TID
Study NCT02826928 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample withdrawn
Study NCT01939444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone intranasal
Description: If bioavailability is 20% or 50 %, the dose will be equivalent to the clinical range 0.4 - 1.0 mg given parenterally
Study NCT01939444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxone intravenous
Description: The parenteral dose reflects clinically used doses for overdoses (0.4 - 1.0 mg). A washout period of at least 3 days between each intervention. IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position
Study NCT00805805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate
Description: 120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime, for one week to test gastric tolerance. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. Serum ceruloplasmin levels measured weekly will be used as a surrogate measure of copper status, with a target of 10-15 mg/dl (normal 20-40). When target Cp levels are reached, usually in 4-8 weeks, a maintenance dose of usually 40-80 mg of TM/day, divided half with a major meal, and half away from food at bedtime will be established (vary from 10 mg to 120 mg/day).
Study NCT00967577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-J591
Description: 70 mCi/m2 of 177Lu-J591 will be administered on Day 1.
Study NCT00805805 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm 2 will basically mirror Arm 1 with the patients receiving 120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime the first week. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. With the dosage being reduced at about the same frequency as the patients receiving TM
Study NCT00002610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin
Study NCT00002610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT04181372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib hydrochloride was given 12mg once daily for two weeks, stop for one week, each 3-week cycle for 2 cycles.
Study NCT04181372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platinum-based chemotherapy medicine
Description: (1)Carboplatin was given dosed to an AUC of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m\^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m\^2 ,i.v. on day 1, pemetrexed was given 500 mg/m\^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m\^2 i.v. on day 1; docetaxel was given 75 mg/m\^2 i.v. on day 1 ,each 21-day cycle for 2 cycles.
Study NCT00002610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00002610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00002610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00002610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00002610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: IV
Study NCT00002610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT02758275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching: Individual (5606)
Description: Usual care and Teaching: Individual (5606): It consists of 6 educational sessions:~1. Behavior Modification (4360) Promotion of a behavior change.~2. Teaching Disease Process (5602) Assisting the patient to understand information related to a specific disease process.~3. Teaching: Prescribed Medication (5616) Preparing a patient to safely take prescribed medications and monitor for their effects.~4. Teaching: Prescribed Diet (5614) Preparing a patient to correctly follow a prescribed diet.~5. Teaching: Prescribed Exercise (5612) Preparing a patient to achieve and/or maintain a prescribed level of activity.~6. Coping Enhancement (5230) Assisting a patient to adapt to perceived stressors, changes, or threats that interfere with meeting life demands and roles.
Study NCT01170676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Puff City GA
Description: Puff City GA focuses on three areas of health behavior: 1) adherence to controller medications; 2) immediate availability of rescue medication; 3)smoking cessation/reduction.
Study NCT01170676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Asthma Education
Description: Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
Study NCT00002610 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01709175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: This is a 13 week strength training program. Sessions will be supervised by a Certified Exercise Physiologist in a group setting.
Study NCT01184040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIP CM
Description: Participants will receive progressively increasing CM for walking 10,000 steps per day over 4 days prior to visit as verified by the pedometer.
Study NCT02015208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 20 mg orally on day 1 to 21 of each 28 day cycle. Number of Cycles: 7 or until progression or unacceptable toxicity develops.
Study NCT00573859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADHD medication
Description: For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication for two consecutive days.
Study NCT00573859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For the placebo condition, participants received placebo pills for two consecutive days.
Study NCT02570919 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IGRT 45 Gy in 5 fractions of 9 Gy
Description: Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
Study NCT02570919 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGRT 24 Gy single dose
Description: Administration of a single dose of 24 Gy in one session
Study NCT03219047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care
Study NCT03219047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given at standard dose and schedule
Study NCT03219047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Derived Xenograft
Description: Xenograft developed
Study NCT03219047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Medicine
Description: Receive treatment based on the results of the PDX models
Study NCT03697551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satoreotide trizoxetan
Description: Subjects will receive a single dose of Satoreotide trizoxetan consisting of a peptide mass up to 45 μg, with a radioactivity range of 150-200 MBq. Satoreotide trizoxetan is intended for diagnostic use as a Positron emission tomography/computed tomography (PET/CT) tracer for the imaging of tumours expressing SSTR2.
Study NCT02605551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Therapy
Description: All OMT techniques will be performed by osteopathic physicians who will have received training specific to this protocol prior to study initiation. All used techniques will be slow moving and gentle to augment rest and relaxation, promote autonomic balance, and release fascial contractures. The techniques that will be used in this protocol are:~1. OM Occipitomastoid release technique~2. Sub-Occipital Release Technique~3. Rib Raising Technique~4. Rotatory stimulation of posterior Chapman's Reflexes~5. Lymphatic Pumps and Effleurage: (Pedal Pump of Dalrymple)
Study NCT02605551 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Modification
Description: Patients will be counseled on healthy behaviors such as regular exercise, weight loss, and a healthy diet
Study NCT02605551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification
Description: Patients will be counseled on healthy behaviors such as regular exercise, weight loss, and a healthy diet
Study NCT00415051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVF MP-12
Description: Administer 1 ml SQ
Study NCT00508313 — intervention group
Intervention type: PROCEDURE
Intervention: Thermal Imaging
Description: Thermal imaging sessions, each taking approximately 10 minutes.
Study NCT05101824 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: SABR
Description: Two fractionation regimes are available (37.5 Gy in 3 fractions and 30.0 Gy in 3 fractions)
Study NCT00744562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-21M18
Description: 0.5, 1, 2.5, 5, and 10 mg/kg weekly until day 56. If patient has not progressed may continue with original dose administered every other week until progression
Study NCT03020459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peeling-reposition
Description: After dying with Brilliant Blue G (BBG, Brilliant Blue; Gender, Germany), a horizontal ILM strip is peeled off in inferior quadrant of macular area. Then the ILM was peeled from inferior to superior area continuously. The ILM roll  was unfolded with assistance of perfluoro-n-octane (PFO). Finally, the position of the fixed ILM flap is adjusted under PFO bubble using flute needle or forceps.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas.Patients are introduced to maintain facedown position for two weeks postoperatively.
Study NCT03020459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peeling
Description: After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany), a horizontal ILM strip is peeled off in inferior quadrant of macular area. Then, the strand of ILM was peeled off radially from the foveal center to vascular arcade. In result, a round -shaped with 2.5-3.5 disc diameter ILM -peeled area was created.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas. Patients are encourage to maintain facedown position for two weeks postoperatively.
Study NCT03020459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brilliant Blue G
Description: We intravitreal injected 0.1ml of Brilliant Blue G (Brilliant Blue; Gender, Germany) to dye ILM before ILM peeling.
Study NCT03020459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilliant Blue G
Description: We intravitreal injected 0.1ml of Brilliant Blue G (Brilliant Blue; Gender, Germany) to dye ILM before ILM peeling.
Study NCT03020459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postoperative posture
Description: Patients of both two groups need to keep prone position for two weeks after the operation.
Study NCT03020459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postoperative posture
Description: Patients of both two groups need to keep prone position for two weeks after the operation.
Study NCT03020459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Constellation 23-gauge vitrectomy system
Description: All surgical procedures are operated on the Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX).
Study NCT03020459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constellation 23-gauge vitrectomy system
Description: All surgical procedures are operated on the Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX).
Study NCT00418769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Study NCT00418769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study NCT02266446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention & Interpretation Modification